Zobrazeno 1 - 10 of 78 pro vyhledávání: '"U Scheuring"'
1
A Blood-based Assay for Assessment of Tumor Mutational Burden in First-line Metastatic NSCLC Treatment: Results from the MYSTIC Study
Autor: Katie Quinn, Jiabu Ye, M. Kuziora, Philip Z Brohawn, F. Liu, Naiyer A. Rizvi, Rajiv Raja, Brandon Higgs, Han Si, Koustubh Ranade, Solange Peters, Kimberly C. Banks, U. Scheuring, Vikram Chand, Elena Helman
Publikováno v: Clinical Cancer Research. 27:1631-1640
Purpose: Tumor mutational burden (TMB) has been shown to be predictive of survival benefit in patients with non–small cell lung cancer (NSCLC) treated with immune checkpoint inhibitors. Measuring TMB in the blood (bTMB) using circulating cell-free
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::37ba13a64c6502b7a31c5d422e234742
https://doi.org/10.1158/1078-0432.ccr-20-3771
Zobrazit plný text záznamu
7
ARCTIC: durvalumab with or without tremelimumab as third-line or later treatment of metastatic non-small-cell lung cancer
Autor: Juergen R. Fischer, M. Powell, Y. Takeda, Michael McCleod, Sergey Orlov, Silvia Novello, S. Mandziuk, Sarayut Lucien Geater, D. Marquez-Medina, David Planchard, R. May, Paul K. Stockman, Niels Reinmuth, Kwang Bo Park, Ross A. Soo, Dariusz M. Kowalski, U. Scheuring, S. Sugawara
Publikováno v: Annals of oncology : official journal of the European Society for Medical Oncology. 31(5)
Many patients with metastatic non-small-cell lung cancer (mNSCLC) experience disease progression after first- and second-line treatment; more treatment options are required for these patients. ARCTIC, a phase III, randomized, open-label study, assess
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3df21e614adbcd5facdd4e9ea97dfc2e
https://pubmed.ncbi.nlm.nih.gov/32201234
Zobrazit plný text záznamu
8
BEGONIA: Phase 1b/2, open-label, platform study of the safety and efficacy of durvalumab (D) ± paclitaxel (P) with novel oncology therapies for first-line metastatic triple-negative breast cancer (mTNBC): Addition of arm 7, D + datopotamab deruxtecan (Dato-DXd; DS-1062)
Autor: Ana Tablante Nunes, Rachel Dougherty, Hannah Dry, U. Scheuring, Vatsala Karwe, Peter Schmid
Publikováno v: Journal of Clinical Oncology. 39:TPS1105-TPS1105
TPS1105 Background: Patients (pts) with mTNBC have limited treatment options and poor prognosis. The combination of immune checkpoint inhibitors with chemotherapy shows promise, but only a subset of pts with mTNBC derive benefit, highlighting the nee
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::3dd7da1ec746b331bf8e540779cbe4ba
https://doi.org/10.1200/jco.2021.39.15_suppl.tps1105
Zobrazit plný text záznamu
9
Efficacy and safety of first-line durvalumab (D) ± tremelimumab (T) vs chemotherapy (CT) in Asian patients with metastatic NSCLC: Results from MYSTIC
Autor: K.H. Lee, Q. Bui, S. Kuyama, U. Scheuring, S. Lucien Geater, Kazuhiko Nakagawa, Tran Van Ngoc, Myung-Ju Ahn, Chin-Chou Wang, J.S. Lee, Virote Sriuranpong, Stephen Clarke, Naiyer A. Rizvi, F. Liu, Eun Kyung Cho, Solange Peters, Delyth Clemett, Byoung Chul Cho
Publikováno v: Annals of Oncology. 30:ix157-ix158
Background In MYSTIC, an open-label, phase 3 trial of first-line D (anti-PD-L1) ± T (anti-CTLA-4) vs CT, while not statistically significant, a clinically meaningful improvement in overall survival (OS) was seen with D vs CT in patients with tumour
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::de3c5ce20ce06b1013b752266f7246e5
https://doi.org/10.1093/annonc/mdz437
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje